PL2167502T3 - Pochodne oksadiazolu i ich zastosowanie jako potencja torów metabotropowego receptora glutaminianowego - Google Patents

Pochodne oksadiazolu i ich zastosowanie jako potencja torów metabotropowego receptora glutaminianowego

Info

Publication number: PL2167502T3
Authority: PL; Poland
Prior art keywords: glutamate receptor; metabotropic glutamate; oxadiazole derivatives; receptor potentiators; potentiators
Prior art date: 2007-06-07

Application number

PL08779348T

Other languages

English (en)

Other versions

PL2167502T6 (pl

Inventor

Joshua Clayton

Ian Egle

James Empfield

James Folmer

Methvin Isaac

Fupeng Ma

Abdelmalik Slassi

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-07

Filing date

2008-06-05

Publication date

2013-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2167502(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2013-01-31 Publication of PL2167502T3 publication Critical patent/PL2167502T3/pl

2013-12-31 Publication of PL2167502T6 publication Critical patent/PL2167502T6/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Epidemiology (AREA)

PL08779348T 2007-06-07 2008-06-05 Pochodne oksadiazolu i ich zastosowanie jako potencja torów metabotropowego receptora glutaminianowego PL2167502T6 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94255307P	2007-06-07	2007-06-07
PCT/SE2008/050666 WO2008150233A1 (en)	2007-06-07	2008-06-05	Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
EP08779348.5A EP2167502B3 (en)	2007-06-07	2008-06-05	Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Publications (2)

Publication Number	Publication Date
PL2167502T3 true PL2167502T3 (pl)	2013-01-31
PL2167502T6 PL2167502T6 (pl)	2013-12-31

Family

ID=40093925

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL11195016T PL2444399T3 (pl)	2007-06-07	2008-06-05	Pochodne oksadiazolu i ich zastosowanie jako potencjatorów metabotropowego receptora glutaminianowego - 842
PL08779348T PL2167502T6 (pl)	2007-06-07	2008-06-05	Pochodne oksadiazolu i ich zastosowanie jako potencja torów metabotropowego receptora glutaminianowego

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL11195016T PL2444399T3 (pl)	2007-06-07	2008-06-05	Pochodne oksadiazolu i ich zastosowanie jako potencjatorów metabotropowego receptora glutaminianowego - 842

Country Status (33)

Country	Link
US (2)	US8377940B2 (pl)
EP (2)	EP2167502B3 (pl)
JP (2)	JP5416696B2 (pl)
KR (2)	KR20150116907A (pl)
CN (2)	CN102977086B (pl)
AR (1)	AR066882A1 (pl)
AU (1)	AU2008260717B2 (pl)
BR (1)	BRPI0812889A2 (pl)
CA (1)	CA2690856C (pl)
CL (1)	CL2008001667A1 (pl)
CO (1)	CO6251287A2 (pl)
CY (2)	CY1113422T1 (pl)
DK (2)	DK2444399T3 (pl)
EC (1)	ECSP109856A (pl)
ES (2)	ES2531443T3 (pl)
HR (2)	HRP20120909T4 (pl)
IL (1)	IL202158A (pl)
ME (1)	ME01488B (pl)
MX (1)	MX2009013078A (pl)
MY (1)	MY158066A (pl)
NZ (1)	NZ582445A (pl)
PE (1)	PE20090328A1 (pl)
PL (2)	PL2444399T3 (pl)
PT (2)	PT2444399E (pl)
RS (2)	RS53845B1 (pl)
RU (2)	RU2470931C2 (pl)
SA (1)	SA08290344B1 (pl)
SI (2)	SI2167502T1 (pl)
TW (1)	TWI417100B (pl)
UA (1)	UA99129C2 (pl)
UY (1)	UY31124A1 (pl)
WO (1)	WO2008150233A1 (pl)
ZA (1)	ZA200908285B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7868008B2 (en) *	2005-08-12	2011-01-11	Astrazeneca Ab	Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) *	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) *	2006-02-16	2008-01-16	Astrazeneca Ab	New metabotropic glutamate receptor-potentiating isoindolones
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TWI417100B (zh) *	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en)	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
CN103342695B (zh)	2007-09-14	2015-04-22	杨森制药有限公司	1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
EP2205565B1 (en)	2007-09-14	2013-04-17	Janssen Pharmaceuticals, Inc.	1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
CA2697399C (en)	2007-09-14	2016-01-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
RU2492170C9 (ru) *	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
SA109300358B1 (ar) *	2008-06-06	2012-11-03	استرازينيكا ايه بي	مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
JP5468068B2 (ja)	2008-06-20	2014-04-09	アストラゼネカ・アクチエボラーグ	ジベンゾチアゼピン誘導体及びその使用
ES2439291T3 (es)	2008-09-02	2014-01-22	Janssen Pharmaceuticals, Inc.	Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
EP2346505B1 (en)	2008-10-16	2014-04-23	Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es)	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
SG176021A1 (en)	2009-05-12	2011-12-29	Janssen Pharmaceuticals Inc	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt)	2009-05-12	2016-04-05	Addex Pharmaceuticals Sa	derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
JP2013516462A (ja) *	2010-01-07	2013-05-13	アストラゼネカ・アクチエボラーグ	代謝調節型グルタミン酸受容体ポジティブアロステリックモジュレーターの製造方法−８７４
SG184449A1 (en) *	2010-04-30	2012-11-29	Astrazeneca Ab	Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
CA2814996C (en)	2010-11-08	2019-10-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (en)	2010-11-08	2015-03-04	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298809B (zh)	2010-11-08	2016-08-31	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102180872B (zh) *	2011-04-01	2014-04-02	华中科技大学	[1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SMT202100103T1 (it)	2014-01-21	2021-03-15	Janssen Pharmaceutica Nv	Combinazione comprendente modulatori allosterici postivi del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
HRP20191646T1 (hr)	2014-01-21	2019-12-13	Janssen Pharmaceutica Nv	Kombinacije koje sadržavaju pozitivne alosteričke modulatore ili ortosteričke agoniste metabotropnog glutamatergičnog receptora podtip 2 i njihova uporaba
TW201713649A (zh)	2015-07-17	2017-04-16	武田藥品工業股份有限公司	雜環化合物
EP3327019A4 (en) *	2015-07-17	2019-04-03	Takeda Pharmaceutical Company Limited	HETEROCYCLIC CONNECTION
US10406146B2 (en)	2015-08-25	2019-09-10	Takeda Pharmaceutical Company Limited	Heterocyclic compound
WO2020102150A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en)	2018-11-13	2022-07-26	Incyte Corporation	Substituted heterocyclic derivatives as PI3K inhibitors
ES2991169T3 (es) *	2019-07-18	2024-12-02	Abaxys Therapeutics	Formulación sólida de un derivado de 1,2,4-oxadiazol
GB2621323A (en) *	2022-08-03	2024-02-14	Sirgartan Holdings Ltd	Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2008803A (en) *	1932-04-18	1935-07-23	Stephan Engineering Corp	Fuel atomizing and igniting means
US3993617A (en)	1975-10-30	1976-11-23	Morton-Norwich Products, Inc.	Antifungal 2-substituted phthalimidines
US5175157A (en)	1985-11-27	1992-12-29	Boehringer Ingelheim Gmbh	Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (en)	1991-04-01	1992-10-15	Kyowa Hakko Kogyo Co., Ltd.	3-methyleneisoindolin-1-one derivative
TW219935B (pl)	1991-12-25	1994-02-01	Mitsubishi Chemicals Co Ltd
EP0602814A1 (en)	1992-12-18	1994-06-22	Takeda Chemical Industries, Ltd.	Crystal forms of optically active isoindolines and their use
US5681954A (en)	1993-05-14	1997-10-28	Daiichi Pharmaceutical Co., Ltd.	Piperazine derivatives
RU2124511C1 (ru) *	1993-05-14	1999-01-10	Фармасьютикал Ко., Лтд	Производные пиперазина
EP0887340A4 (en)	1996-02-06	2000-03-29	Japan Tobacco Inc	CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO1998054135A1 (fr)	1997-05-30	1998-12-03	Meiji Seika Kaisha, Ltd.	Composes heterocycliques azotes et medicament contre l'hyperlipemie en contenant
CA2311131A1 (en)	1997-11-21	1999-06-03	Nps Pharmaceuticals, Inc.	Metabotropic glutamate receptor antagonists for treating central nervous system diseases
DK1260512T3 (da)	2000-02-29	2007-11-05	Mitsubishi Pharma Corp	Hidtil ukendte, cykliske amidderivater
AU2001278508A1 (en)	2000-07-31	2002-02-13	Smithkline Beecham P.L.C.	Carboxamide compounds and their use as antagonists of a human 11cby receptor
RU2270192C2 (ru) *	2001-04-19	2006-02-20	Эйсай Ко., Лтд.	Производные 2-иминопирролидина
CA2457468A1 (en)	2001-08-09	2003-02-27	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient
WO2003087044A2 (en)	2002-04-09	2003-10-23	7Tm Pharma A/S	Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr)	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de)	2002-08-24	2004-03-11	Boehringer Ingelheim International Gmbh	Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en)	2002-10-07	2002-11-13	Pfizer Ltd	Chemical compounds
AU2003284669B2 (en) *	2002-11-26	2009-11-12	Maruishi Pharmaceutical Co., Ltd.	Isoindoline derivative
WO2004087048A2 (en)	2003-03-26	2004-10-14	Merck & Co. Inc.	Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en)	2003-04-07	2003-05-14	Glaxo Group Ltd	Compounds
US7129260B2 (en)	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors
US20070135485A1 (en)	2003-10-22	2007-06-14	Gillig James R	Novel mch receptor antagonists
WO2005074643A2 (en)	2004-01-30	2005-08-18	Smithkline Beecham Corporation	Benzamide compounds useful as rock inhibitors
MY152888A (en) *	2004-02-18	2014-11-28	Astrazeneca Ab	Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
HRP20141241T1 (hr)	2004-03-05	2015-02-13	Nissan Chemical Industries, Ltd.	Spoj benzamida supstituiran izoksazolinom i sredstvo za suzbijanje štetnih organizama
US7902369B2 (en)	2004-03-05	2011-03-08	Banyu Pharmaceutical Co., Ltd.	Diaryl-substituted five-membered heterocycle derivative
SE0400970D0 (sv)	2004-04-14	2004-04-14	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
TW200613272A (en)	2004-08-13	2006-05-01	Astrazeneca Ab	Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CN101048157A (zh)	2004-10-25	2007-10-03	默克公司	代谢型谷氨酸受体的杂环二氢茚酮增强剂
WO2006091496A2 (en)	2005-02-24	2006-08-31	Merck & Co., Inc.	Benzazole potentiators of metabotropic glutamate receptors
GB0510142D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds A1
MX2007014444A (es) *	2005-05-18	2008-04-21	Addex Pharmaceuticals Sa	Derivados de oxadiazol sustituido como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
TW200728277A (en)	2005-06-29	2007-08-01	Palau Pharma Sa	Bicyclic derivatives as P38 inhibitors
CN101277934A (zh) *	2005-08-12	2008-10-01	阿斯利康(瑞典)有限公司	使代谢型谷氨酸-受体-增效的异吲哚酮
US7868008B2 (en)	2005-08-12	2011-01-11	Astrazeneca Ab	Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en)	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
JP5048675B2 (ja) *	2005-09-27	2012-10-17	エフ．ホフマン−ラロシュアーゲー	ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
TW200804281A (en)	2006-02-16	2008-01-16	Astrazeneca Ab	New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en)	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh)	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途

2008
- 2008-06-04 TW TW097120762A patent/TWI417100B/zh not_active IP Right Cessation
- 2008-06-05 ES ES11195016.8T patent/ES2531443T3/es active Active
- 2008-06-05 KR KR1020157026785A patent/KR20150116907A/ko not_active Ceased
- 2008-06-05 WO PCT/SE2008/050666 patent/WO2008150233A1/en active Application Filing
- 2008-06-05 US US12/663,371 patent/US8377940B2/en not_active Expired - Fee Related
- 2008-06-05 UA UAA200911794A patent/UA99129C2/ru unknown
- 2008-06-05 CA CA2690856A patent/CA2690856C/en not_active Expired - Fee Related
- 2008-06-05 ES ES08779348T patent/ES2393425T7/es active Active
- 2008-06-05 JP JP2010511147A patent/JP5416696B2/ja not_active Expired - Fee Related
- 2008-06-05 BR BRPI0812889A patent/BRPI0812889A2/pt not_active IP Right Cessation
- 2008-06-05 RS RS20150130A patent/RS53845B1/en unknown
- 2008-06-05 RU RU2009147708/04A patent/RU2470931C2/ru not_active IP Right Cessation
- 2008-06-05 KR KR1020097025404A patent/KR20100017640A/ko not_active Ceased
- 2008-06-05 PL PL11195016T patent/PL2444399T3/pl unknown
- 2008-06-05 SI SI200830807T patent/SI2167502T1/sl unknown
- 2008-06-05 DK DK11195016T patent/DK2444399T3/en active
- 2008-06-05 DK DK08779348.5T patent/DK2167502T3/da active
- 2008-06-05 MY MYPI20095187A patent/MY158066A/en unknown
- 2008-06-05 RS RS20120507A patent/RS52526B2/sr unknown
- 2008-06-05 MX MX2009013078A patent/MX2009013078A/es active IP Right Grant
- 2008-06-05 AU AU2008260717A patent/AU2008260717B2/en not_active Ceased
- 2008-06-05 SI SI200831385T patent/SI2444399T1/sl unknown
- 2008-06-05 AR ARP080102401A patent/AR066882A1/es unknown
- 2008-06-05 PT PT11195016T patent/PT2444399E/pt unknown
- 2008-06-05 EP EP08779348.5A patent/EP2167502B3/en active Active
- 2008-06-05 NZ NZ582445A patent/NZ582445A/en not_active IP Right Cessation
- 2008-06-05 PT PT08779348T patent/PT2167502E/pt unknown
- 2008-06-05 HR HRP20120909AT patent/HRP20120909T4/hr unknown
- 2008-06-05 ME MEP-2012-131A patent/ME01488B/me unknown
- 2008-06-05 CN CN201210486921.4A patent/CN102977086B/zh not_active Expired - Fee Related
- 2008-06-05 CN CN2008800191548A patent/CN101679403B/zh not_active Expired - Fee Related
- 2008-06-05 PL PL08779348T patent/PL2167502T6/pl unknown
- 2008-06-05 EP EP11195016.8A patent/EP2444399B1/en active Active
- 2008-06-06 PE PE2008000965A patent/PE20090328A1/es not_active Application Discontinuation
- 2008-06-06 US US12/134,553 patent/US8377939B2/en not_active Expired - Fee Related
- 2008-06-06 UY UY31124A patent/UY31124A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001667A patent/CL2008001667A1/es unknown
- 2008-06-07 SA SA08290344A patent/SA08290344B1/ar unknown
2009
- 2009-11-16 IL IL202158A patent/IL202158A/en not_active IP Right Cessation
- 2009-11-23 ZA ZA200908285A patent/ZA200908285B/xx unknown
- 2009-12-04 CO CO09139153A patent/CO6251287A2/es not_active Application Discontinuation
2010
- 2010-01-06 EC EC2010009856A patent/ECSP109856A/es unknown
2012
- 2012-09-25 RU RU2012141706/04A patent/RU2012141706A/ru not_active Application Discontinuation
- 2012-11-22 CY CY20121101132T patent/CY1113422T1/el unknown
2013
- 2013-11-14 JP JP2013235538A patent/JP5815644B2/ja not_active Expired - Fee Related
2015
- 2015-02-24 HR HRP20150210TT patent/HRP20150210T1/hr unknown
- 2015-02-26 CY CY20151100204T patent/CY1116150T1/el unknown

Also Published As

Publication number	Publication date
RS52526B (en)	2013-04-30
KR20150116907A (ko)	2015-10-16
RS53845B1 (en)	2015-08-31
PT2444399E (pt)	2015-03-04
HRP20120909T4 (hr)	2013-11-08
EP2167502A1 (en)	2010-03-31
RU2470931C2 (ru)	2012-12-27
KR20100017640A (ko)	2010-02-16
JP5416696B2 (ja)	2014-02-12
CY1113422T1 (el)	2016-06-22
CA2690856C (en)	2015-12-15
UA99129C2 (ru)	2012-07-25
CN101679403B (zh)	2013-01-02
US8377939B2 (en)	2013-02-19
WO2008150233A1 (en)	2008-12-11
HK1166978A1 (en)	2012-11-16
NZ582445A (en)	2012-03-30
CN102977086B (zh)	2015-04-01
CN102977086A (zh)	2013-03-20
UY31124A1 (es)	2009-01-30
MY158066A (en)	2016-08-30
RU2012141706A (ru)	2014-03-27
PL2167502T6 (pl)	2013-12-31
EP2167502B1 (en)	2012-09-19
EP2444399A1 (en)	2012-04-25
BRPI0812889A2 (pt)	2017-05-23
US8377940B2 (en)	2013-02-19
CY1116150T1 (el)	2017-02-08
IL202158A0 (en)	2010-06-16
TW200911254A (en)	2009-03-16
JP2014055164A (ja)	2014-03-27
US20080306077A1 (en)	2008-12-11
IL202158A (en)	2015-11-30
JP5815644B2 (ja)	2015-11-17
ES2531443T3 (es)	2015-03-16
DK2444399T3 (en)	2015-03-02
ES2393425T7 (es)	2013-11-22
CO6251287A2 (es)	2011-02-21
HRP20120909T1 (en)	2012-12-31
DK2167502T3 (da)	2012-12-03
EP2167502A4 (en)	2011-04-06
AR066882A1 (es)	2009-09-16
PT2167502E (pt)	2012-11-26
JP2010529118A (ja)	2010-08-26
RU2009147708A (ru)	2011-07-20
RS52526B2 (sr)	2018-06-29
SA08290344B1 (ar)	2011-10-03
SI2444399T1 (sl)	2015-03-31
AU2008260717B2 (en)	2012-01-19
PL2444399T3 (pl)	2015-04-30
HRP20150210T1 (en)	2015-06-05
ZA200908285B (en)	2010-08-25
CL2008001667A1 (es)	2009-03-06
ES2393425T3 (es)	2012-12-21
SI2167502T1 (sl)	2012-12-31
ECSP109856A (es)	2010-02-26
EP2444399B1 (en)	2014-11-26
ME01488B (me)	2014-04-20
TWI417100B (zh)	2013-12-01
CN101679403A (zh)	2010-03-24
EP2167502B3 (en)	2013-07-10
US20100267740A1 (en)	2010-10-21
HK1142318A1 (en)	2010-12-03
AU2008260717A1 (en)	2008-12-11
CA2690856A1 (en)	2008-12-11
PE20090328A1 (es)	2009-04-24
MX2009013078A (es)	2010-01-15

Publication	Publication Date	Title
IL202158A0 (en)	2010-06-16	Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
EP2167501A4 (en)	2011-03-30	OXADIAZOLE LIGANDS FROM METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE AS POTENTIALIZERS - 841
ZA201008611B (en)	2012-05-30	Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
ZA201001860B (en)	2011-05-25	Pyridazinone derivatives and use thereof as p2z7 receptor inhibitors
IL188809A0 (en)	2008-08-07	Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
ZA201104423B (en)	2012-03-28	Oxadiazole derivatives
IL213168A0 (en)	2011-07-31	1,2,4-oxadiazole derivatives and their therapeutic use
IL210834A0 (en)	2011-04-28	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
IL194082A0 (en)	2009-08-03	Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
IL211042A0 (en)	2011-04-28	Imidazopyridin-2-one derivatives and uses thereof
IL177056A0 (en)	2006-12-10	Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
ZA201103635B (en)	2012-10-31	Azaquinolinone derivatives and uses thereof
EP2184278A4 (en)	2011-08-03	P2X4 RECEIVER ANTAGONIST
SI2195293T1 (sl)	2014-02-28	Derivati ciklopropil amida
ZA200903574B (en)	2010-08-25	2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL195972A0 (en)	2009-09-01	Cinnamoyl-piperazine derivatives and their use as par-i antagonists
IL208771A0 (en)	2010-12-30	Iminopyridine derivatives and use thereof
IL206951A0 (en)	2010-12-30	3-alkyl-piperazine derivatives and uses thereof
HK1142609A (en)	2010-12-10	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators - 841
HK1137021A (en)	2010-07-16	Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
HK1130492A (en)	2009-12-31	Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
HK1155721A (en)	2012-05-25	Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists
IL206950A0 (en)	2010-12-30	Aminopiperidinyl derivatives and uses thereof